Genprex to Unveil Encouraging Data on REQORSA(R) at AACR-NIH-EORTC Conference
LOS ANGELES, CA - (NewMediaWire) - October 06, 2023 - (InvestorBrandNetwork via NewMediaWire) - IBN, a multifaceted financial news, content creation and publishing company, is utilized by both public and private companies to optimize investor awareness and recognition.
Genprex (NASDAQ: GNPX) is at the forefront of pioneering cancer treatments, and it's making waves with remarkable advancements in lung cancer therapy. The company will be sharing compelling clinical and preclinical data at the prestigious 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15 at the Hynes Convention Center in Boston.
The Acclaim-1 Phase 1 study results have demonstrated the safety and efficacy of REQORSA(R) in combination with Tagrisso(R), bringing hope to patients with late-stage NSCLC. Moreover, preclinical studies have highlighted REQORSA(R)'s potential in combination with a checkpoint inhibitor to combat chemotherapy-resistant small cell lung cancer ("SCLC").
Two simultaneous presentations will showcase the company's advancements on October 12 from 12:30 pm 4:00 pm ET. Alexander I. Spira, M.D., PhD, Virginia Cancer Specialists, Fairfax, VA will be presenting "Completion of Acclaim-1 dose escalation: Recommended Phase 2 dose of quaratusugene ozeplasmid gene therapy and osimertinib."
Concurrently, Ismail Meraz, Ph.D., Senior Research Project Manager, The University of Texas MD Anderson Cancer Center will be presenting "TUSC2 immunogene therapy enhances checkpoint blockade through increased cytotoxic immune activation in chemo-resistant small cell lung cancer (SCLC) in humanized mice."
To view the full press release, visit https://ibn.fm/xXElV
About Genprex Inc.
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral ONCOPREX(R) Nanoparticle Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The company's lead product candidate, REQORSA(R) (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer ("NSCLC") and small cell lung cancer ("SCLC"). Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the Food and Drug Administration ("FDA"), and its SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus ("AAV") vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-003 for type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, visit the company's website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company's newsroom at http://ibn.fm/GNPX
About IBN
IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
